ARCHIVES

FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.

This article is from The Cancer Letter archive.

Vol. 31 No. 02 | January 14, 2005

Download PDF Visit The Full Archive

Related Articles

Anti-Estrogen Drug Therapy Reduces Risk of Invasive Breast Cancer In Older Women

July 25, 2008

Three Win Nobel Prize In Medicine; Irving Center Awarded $10M For Breast Cancer Research.

October 13, 2000

Clinical Education Program Phase Out Opposed By NCAB Committee

February 14, 1986

Advocacy Groups Form Council To Lobby For Cancer Programs To Benefit Minorities

April 28, 1995

NIH Study Finds Sigmoidoscopy Reduces Colon Cancer Incidence and Mortality Rates

May 25, 2012

NCI CTEP-Approved Trials For the Month of July

July 25, 2014